Deciphera Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Deciphera Pharmaceuticals's estimated annual revenue is currently $91.4M per year.
- Deciphera Pharmaceuticals received $128.0M in venture funding in October 2017.
- Deciphera Pharmaceuticals's estimated revenue per employee is $235,670
- Deciphera Pharmaceuticals's total funding is $886.5M.
- Deciphera Pharmaceuticals's current valuation is $518.7M. (January 2022)
Employee Data
- Deciphera Pharmaceuticals has 388 Employees.
- Deciphera Pharmaceuticals grew their employee count by 21% last year.
Deciphera Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Quality Assurance | Reveal Email/Phone |
2 | VP Analytical Development & Quality Control | Reveal Email/Phone |
3 | VP, New Product Planning | Reveal Email/Phone |
4 | VP Marketing, Sales and Commercial Training | Reveal Email/Phone |
5 | VP Regulatory Affairs | Reveal Email/Phone |
6 | VP, Chemical Development & Manufacturing | Reveal Email/Phone |
7 | SVP, General Counsel | Reveal Email/Phone |
8 | VP, Information Technology and Facilities | Reveal Email/Phone |
9 | SVP, Head International | Reveal Email/Phone |
10 | Head Global Medical Affairs | Reveal Email/Phone |
Deciphera Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a 'switched off or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$886.5M
Total Funding
388
Number of Employees
$91.4M
Revenue (est)
21%
Employee Growth %
$518.7M
Valuation
N/A
Accelerator
Deciphera Pharmaceuticals News
... Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals ... Johnson & Johnson is usually the first pharma company to report...
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting. ULK Inhibitor DCC-3116 Shown to Inhibit...
Deciphera Pharmaceuticals Inc. is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of...
Deciphera Announces Positive CHMP Opinion for QINLOCK®for the Treatment of Fourth-line Gastrointestinal Stromal Tumor - European Commission Decision Anticipated by the Fourth Quarter of 2021 - Waltham, MA - September 17, 2021 - Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage ...
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $134.7M | 399 | 6% | N/A |
#2 | $24.6M | 400 | 96% | N/A |
#3 | N/A | 407 | -1% | $264.9M |
#4 | $92.5M | 411 | -11% | N/A |
#5 | $75.8M | 418 | N/A | N/A |
Deciphera Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-12-24 | $15.0M | Lead Investor: Undis | Article | |
| 2015-09-22 | $75.0M | B | New Leaf Venture Partners | Article |
| 2016-01-06 | $90.0M | B | New Leaf Venture Partners | Article |
| 2017-06-05 | $52.0M | Undisclosed | Viking Global Investors LP | Article |
| 2017-10-02 | $128.0M | Undisclosed | Article |